Averting a pandemic health crisis in Europe by 2020: What physicians need to know regarding cholesterol management

European Journal of Preventive Cardiology

Volumn 14, Issue 2, 2007, Pages 340-345

  Catapano, Alberico L ^a   Pedersen, Terje R ^b   de Backer, Guy ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

cardiovascular disease; cholesterol; cholesterol lowering therapies

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; HEALTH CARE PERSONNEL; HEALTH PROMOTION; HUMAN; LIFESTYLE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; CHOLESTEROL; EUROPE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICIAN'S ROLE; PRIMARY PREVENTION; RISK ASSESSMENT; WORLD HEALTH;

EID: 34247502473     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0b013e3280122868     Document Type: Article

References (26)

1. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics, 2005edition. European Heart Network. Available at:www.ehnheart.org/files/statistics%202005–092711A.pdf.Accessed: 3 June 2006.
2. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovasculardisease prevention in clinical practice: third joint task force of Europeanand other societies on cardiovascular disease prevention in clinicalpractice (constituted by representatives of eight societies and by invitedexperts). Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl1):S1–S78.
3. Hockley T, Pollard S, Sedgley M. Cholesterol: the public policy implications of not doing enough.1–24. 2006. London, UnitedKingdom: Stockholm Network.Available at:http://www.stockholm-network.org/downloads/publications/d41d8cd9-Cholesterol%20Report.pdf.Accessed: November 2006.
4. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortalityfindings for men screened in the Multiple Risk Factor Intervention Trial.Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490–1500.
5. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The WhitehallStudy. JAMA 1992; 267: 70–76.
6. Lifestyle and risk factor management and use of drug therapies incoronary patients from 15 countries; principal results from EUROASPIRE IIEuro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.
7. Editorial.Compliance or concordance: is there adifference? Drug Ther Perspect 1999; 13: 11–12.
8. Lipsy RJ. Effective management of patients with dyslipidemia. Am J Manag Care 2003; 9(Suppl):S39–S58.
9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487–497.
10. Davidson MH. Strategies to improve Adult Treatment Panel III guidelineadherence and patient compliance. Am J Cardiol 2002; 89: 8C–20C.
11. Varady KA, Jones PJ. Combination diet and exercise interventions for the treatment ofdyslipidemia: an effective preliminary strategy to lower cholesterollevels? J Nutr 2005; 135: 1829–1835.
12. Umans-Eckenhausen MA, Defesche JC, Scheerder RL, Cline F, Kastelein JJ. Tracing of patients with familial hypercholesterolemia in theNetherlands [in Dutch]. Ned Tijdschr Geneeskd 1999; 143: 1157–1161.
13. van Zwieten PA, Farsang C. Combination of antihypertensive drugs from a historicalperspective. Blood Press 2005; 14: 72–79.
14. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trialsfor the National Cholesterol Education Program Adult Treatment Panel IIIGuidelines. J Am Coll Cardiol 2004; 44: 720–732.
15. MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatinin 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
16. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering withatorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.
17. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid loweringwith statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.
18. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared withmoderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial. JAMA 2004; 291: 1071–1080.
19. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statintherapy on regression of coronary atherosclerosis: the ASTEROID Trial. JAMA 2006; 295: 1556–1565.
20. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dosesimvastatin for secondary prevention after myocardial infarction: the IDEALstudy: a randomized controlled trial. JAMA 2005; 294: 2437–2445.
21. Pitt B. Low-density lipoprotein cholesterol in patients with stablecoronary heart disease — is it time to shift ourgoals? N Engl J Med 2005; 352: 1483–1484.
22. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-administering ezetimibe with on-going simvastatintreatment on LDL-C goal attainment in hypercholesterolemic patients withcoronary heart disease. Int J Cardiol 2005; 102: 327–332.
23. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered withatorvastatin in 628 patients with primary hypercholesterolemia: aprospective, randomized, double-blind trial. Circulation 2003; 107: 2409–2415.
24. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, et al. Achieving lipoprotein goals in patientsat high risk with severe hypercholesterolemia: efficacy and safety ofezetimibe co-administered with atorvastatin. Am Heart J 2004; 148: 447–455.
25. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across theirdose ranges in patients with hypercholesterolemia and without activearterial disease. Am J Cardiol 2003; 91: 33–41.
26. Scharnagl H, Marz W. New lipid-lowering agents acting on LDL receptors. Curr Top Med Chem 2005; 5: 233–242